Clinical Trials Logo

Clinical Trial Summary

This study is a prospective, multicentre, interventional cohort study in children with PWS over 4 years (no treatment administered). The duration of the preceding OTTB3 study is 26 weeks. An untreated cohort of children with PWS will be included at an age of 2 years and followed up until an age of 4 years. Regarding the untreated cohort, children with PWS born in France and too old to be recruited in OTBB3 trial, principally those who were born within one year before the start of OTBB3 trial, will be offered to participate in this study. Infants born later who couldn't be included in OTBB3 study will be also offered to participate.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05032326
Study type Interventional
Source University Hospital, Toulouse
Contact Maithé TAUBER, MD
Phone 534 55 85 51
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date August 30, 2021
Completion date April 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04526379 - Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation N/A
Terminated NCT03458416 - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome Phase 2
Active, not recruiting NCT03718416 - Natural History Study of Serious Medical Events in PWS
Terminated NCT02179151 - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Phase 3
Not yet recruiting NCT02205450 - Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell N/A
Completed NCT00375089 - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity N/A
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Not yet recruiting NCT03831425 - Mitochondrial Complex I Dysfunction in PWS Phase 2
Recruiting NCT03031626 - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Phase 4
Withdrawn NCT04086810 - An Open-Label Study of DCCR Tablet in Patients With PWS Phase 3
Active, not recruiting NCT02629991 - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Phase 2
Recruiting NCT02297022 - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome Phase 1
Not yet recruiting NCT02263781 - PREPL in Health and Disease N/A
Completed NCT00551343 - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome N/A
Not yet recruiting NCT04484051 - Global Growth Hormone Study in Adults With Prader-Willi Syndrome Phase 3
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Active, not recruiting NCT03714373 - Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Phase 3
Completed NCT03114371 - Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years N/A
Recruiting NCT03848481 - CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) Phase 2
Completed NCT00705172 - Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome N/A